COMPARISON OF THREE DIFFERENT RISK CALCULATOR TO PREDICT PROSTATE CANCER BEFORE BIOPSY - RESULTS FROM A RETROSPECTIVE STUDY IN ZURICH

You have accessJournal of UrologyProstate Cancer: Detection & Screening III1 Apr 2014MP63-10 COMPARISON OF THREE DIFFERENT RISK CALCULATOR TO PREDICT PROSTATE CANCER BEFORE BIOPSY - RESULTS FROM A RETROSPECTIVE STUDY IN ZüRICH Cedric Poyet, Martin Umbehr, Caroline Wiederkehr, Remo Largo, Tullio Sulser, and Thomas Hermanns Cedric PoyetCedric Poyet More articles by this author , Martin UmbehrMartin Umbehr More articles by this author , Caroline WiederkehrCaroline Wiederkehr More articles by this author , Remo LargoRemo Largo More articles by this author , Tullio SulserTullio Sulser More articles by this author , and Thomas HermannsThomas Hermanns More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1947AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Several risk calculator have been developed to predict the outcome of prostate biopsies. Which of the risk calculators perform best in Switzerland is not known. We compared the predictive accuracy of three commonly used nomograms by comparing their prostate biopsy outcome predictions with actual pathological results. METHODS 1885 patients who underwent a transrectal prostate biopsy between 2003 and 2012 were retrospectively analysed. Patients older than 70 years and or with a PSA level over 50 ug/l were excluded. The probability of a positive biopsy was calculated using three known risk calculator (SWOP-PRI, PCPT-CRC & Montreal). The probability of the model was compared with the actual results of the biopsy. To study statistical associations Chi-Square test, Mann-Whitney test and die Area under the Curve was used. RESULTS 440 (23.34 %) of 1885 patients were diagnosed with prostate cancer. Among the three risk calculators the PCPT-CRC showed the highest accuracy in predicting a positive prostate biopsy (AUC for: PCPC 0,641; SWOP-PRI 0,633; Montreal 0,609; PSA 0,564). Moreover the PCPT-CRC showed the highest accuracy in predicting high grade prostate cancer (>= Gleason 7) before biopsy (AUC for: PCPC 0,733; SWOP-PRI 0,714; Montreal 0,656; PSA 0,637). CONCLUSIONS The external validation of three commonly used nomograms designed to predict the likelihood of a positive biopsy cancer revealed that the PCPT-CRC model was more accurate than the SWOP-PRI or the Montreal Model. Moreover the PCPT-CRC model revealed the highest accuracy to detect high grade prostate cancer. All models performed better than PSA alone © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e712 Advertisement Copyright & Permissions© 2014Metrics Author Information Cedric Poyet More articles by this author Martin Umbehr More articles by this author Caroline Wiederkehr More articles by this author Remo Largo More articles by this author Tullio Sulser More articles by this author Thomas Hermanns More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...